Pfizer has announced that its lung cancer drug, Lorbrena, is projected to generate over $1 billion in annual sales by 2030, driven by positive clinical trial results.
Pfizer Anticipates $1 Billion Annual Sales of Lorbrena
According to Reuters, data released on Friday revealed that a majority of patients with a rare form of advanced lung cancer in a clinical trial had no disease progression for five years and were still alive after treatment with Lorbrena.
Lorbrena targets a specific gene mutation called anaplastic lymphoma kinase (ALK), similar to Pfizer's earlier drug, Xalkori.
Results from the company's Phase 3 CROWN trial revealed at the Chicago's American Society of Clinical Oncology annual meeting showed that 60% of ALK-positive patients treated with Lorbrena experienced no disease progression after five years, a stark contrast to the 8% for those treated with Xalkori.
Additionally, 53% of Lorbrena patients with brain metastases were disease-free after five years.
Sales of Lobrena Surge
Since its US approval in March 2021, Lorbrena's sales have surged, reaching $164 million in the first quarter of 2024, a 46% increase from the previous year.
Pfizer anticipates continued double-digit growth for the drug, which is vital to its strategy to offset declining COVID-19 vaccine sales and refocus on its oncology portfolio.
Join the Conversation